Carbonic anhydrase IX has been under intensive investigation as a therapeutic target
in cancer. Studies demonstrate that this enzyme has a key role in pH regulation in cancer cells,
allowing these cells to adapt to the adverse conditions of the tumour microenviroment. Novel
CAIX inhibitors have shown efficacy in both in vitro and in vivo pre-clinical cancer models, adversely
affecting cell viability, tumour formation, migration, invasion, and metastatic growth when used
alone. In co-treatments, CAIX inhibitors may enhance the effects of anti-angiogenic drugs or
chemotherapy agents [PMID: 29439394].
中文
